Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

May 02 2024

• By Jessica Merrill

hour glass — Regeneron signaled a possible delay for Dupixent in COPD • Source: Shutterstock

Related Content

Dupixent Heralds The Age Of Biologics In COPD

Nov 27 2023

UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals

Aug 18 2023

Regeneron Buys Partner Decibel Outright

Aug 10 2023

Many New Frontiers Ahead For Regeneron

Jan 16 2024

Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval

Mar 25 2024

Related Companies

Regeneron Pharmaceuticals, Inc.

Sanofi

Roche Holding AG

Decibel Therapeutics, Inc.

Additional Topics

Business Strategies Immune Disorders Inflammation Metabolic Disorders BioPharmaceutical

More from Immunological

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.